SPOTLIGHT

STAY CONNECTED

LinkedIn  

STARTUP NEWS

WUXI NEWS

WuXi NextCODE Completes $240 Million Series B Financing

We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series B round with investment from a consortium...

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics CGMP Manufacturing Facilities for...

We are pleased to announce that the U.S. Food and Drug Administration has completed the Pre-License Inspection (PLI) of WuXi Biologics cGMP manufacturing facilities for production of TMB-355 (ibalizumab) with no...

WuXi’s Pharmaceutical Development Services Division Merges with STA

We are excited to announce that WuXi subsidiary STA Pharmaceutical Co., Ltd. (STA)  has merged with our Pharmaceutical Development Services (PDS) division. The PDS division offers pre-formulation development, formulation development, as...

STA Signs Supply Agreement with TESARO

We are pleased to announce that STA Pharmaceutical Co., Ltd. (STA), a WuXi subsidiary, has signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. for certain starting and intermediate...

China Market Authorization Holder System Summit 2017 Recap

More than 300 professionals gathered at the recent China Marketing Authorization Holder (MAH) System Summit to learn from government agencies, life science research and drug development scientists, and drug development and...

FDA UPDATES